	<b>PCI group</b> (n = 475)		CABG group (n = 226)		
Clinical outcome	HR (95%CI) <sup>a</sup>	P <sup>a</sup>	HR (95%CI) <sup>a</sup>	P <sup>a</sup>	<b>P</b> interaction <sup>b</sup>
MACE	1.57 (1.28-1.93)	< 0.001	1.58 (1.12-2.22)	0.009	0.98
All-cause death	2.00 (1.51-2.67)	< 0.001	1.73 (1.00-2.98)	0.048	0.64
Cardiac death	2.01 (1.33-3.03)	< 0.001	1.33 (0.63-2.80)	0.454	0.34
Repeat revascularization	1.28 (0.94-1.73)	0.114	1.48 (0.89-2.46)	0.131	0.63
MI/stroke	1.35 (0.89-2.05)	0.159	1.64 (0.43-6.33)	0.472-	0.79

Table S1. Associations of mtDNA 8-OHdG with 1-year clinical outcomes stratified by revascularization modality.

<sup>*a*</sup> Models were adjusted for age, sex, smoking habit, alcohol drinking habit, overweight/obesity, hypertension, dyslipidemia., FPG, HbA1c, diabetes duration, and type of diabetes management.

 $^{b}$  P<sub>interaction</sub> was obtained from the  $\chi$ 2-based Q test.